Introduction: The occurrence of multiple β-lactamases among bacteria only limits the therapeutic options but also poses a challenge. A study
Introduction
The rapid global dissemination of Enterobacteriaceae harboring plasmid-borne extended-spectrum β-lactamases (ESBLs) and plasmid-mediated AmpC β-lactamases represents a significant clinical threat [1, 2] . ESBLs producing organism confer resistance to penicillin, cephalosporins, and monobactams. They cannot hydrolyze cephamycins and are inhibited by clavulanic acid (CA) [3] . Like ESBLs, plasmid-mediated AmpC β-lactamases have a broad substrate profile that includes penicillin, cephalosporins, and monobactams. In contrast to ESBLs, they hydrolyze cephamycins and are not inhibited by commercially available β-lactamase inhibitors [4, 5] . Inappropriate use of cephalosporins in clinical practice led to the emergence of bacteria producing multiple β-lactamases. This leads to therapeutic failure when β-lactam drugs or β-lactam/inhibitor combination are used [6 ] . The ESBL confirmation methods have been established by Clinical Laboratory Standards Institute (CLSI) and are used worldwide [7] . Currently there are no CLSI recommended guidelines to detect AmpC β-lactamases. Several methods of phenotypic detection of AmpC β-lactamases are described; however, these methods are labor intensive and subjective, lack sensitivity and/or specificity and cannot be adopted on a routine basis.PCR gives satisfactory results, but it is costlier and time consuming, and equipment availability is limited to few laboratories [8] [9] [10] [11] [12] [13] [14] [15] . The CLSI recommended phenotypic confirmatory test would fail to detect ESBL in the presence of AmpC, as the latter enzyme is resistant to clavulanic acid [10] . Clavulanic acid induces high level expression of chromosomal AmpC β-lactamases, masking the synergy arising from the inhibition of an ESBL. Thus, the coexistence of both ESBL and AmpC β-lactamases in the same strain may result in false-negative tests for the detection of ESBLs [16] . Boronic acid (BA) derivatives were reported as reversible inhibitors of AmpC enzymes [17, 18] . Several studies have validated the use of boronic acid to detect AmpC β-lactamases among Gram-negative bacteria [16, [19] [20] [21] . Rapid and accurate detection of ESBLs and AmpC β-lactamases is important to guide proper antimicrobial therapy and for appropriate infection control measures. Therefore the present study was aimed to evaluate the usage of boronic acid in a phenotypic confirmatory test to detect ESBL among AmpC β-lactamases producing isolates.
Methods

Bacterial isolates
A total of 259 consecutive nonrepetitive clinical isolates of Enterobacteriaceae were isolated from various clinical samples such as urine (n= 103), pus (n=83), sputum (n= 60), blood (n= 9) over a period of six months from January 2010 to June 2010. Samples were processed and isolates were identified on the basis of conventional microbiological procedures [22] .
Antimicrobial susceptibility testing
Antibiotic susceptibility was determined by Kirby-Bauer disk diffusion method and the results were interpreted according to the guidelines of the Clinical Laboratory Standard Institute [23] . The antibiotics used were ampicillin (10µg), ticarcillin(75µg), piperacillin(100µg), amoxycillin/ clavulanic acid (20/10µg), ticarcillin/clavulanic acid (75/10µg), piperacillin-tazobactum (100/10µg), aztreonam (30µg), cephotaxime (30µg), ceftazidime(30µg), ceftriaxone (30µg), cefepime (30µg), impenem (10µg), gentamicin (10µg), amikacin (30µg), tetracycline (30µg) and ciprofloxacin (5µg), chloramphenicol (30µg). E. coli ATCC 25922 was used as a quality control strain.
All the 259 isolates were screened for ESBL production by (i) CLSI double-disk diffusion method [23] (ii) cefepime-clavulanic acid method (iii) boronic disk potentiation method. AmpC production was detected using cefoxitin alone and in combination with boronic acid and confirmation was done by three dimensional disk method. Briefly, 5µl of the freshly prepared clavulanic acid (2g/l of PBS at pH 6) was added to cefotaxime (30µg; CTX+CA) and cefepime (30µg; CPM+CA) disks. Then 5 µl of 3-amino phenyl boronic acid (Sigma Aldrich, India) stock solution (60g/l of DMSO) was added to cefotaxime disc with(CTX+CA+BA) and without clavulanic acid(CTX+BA) and also to cefoxitin disc(FOX+BA). The discs were placed onto Mueller hinton agar plates containing lawn culture of 0.5 McFarland unit of test organism. The plates were incubated at 37° C for 18-24 hrs. The results were interpreted as follows: 
Results
Of 
Discussion
The occurrence of multiple β-lactamases among bacteria only limits the therapeutic options but also poses a challenge for microbiology laboratories to identify them [6] . The detection of the co-production of ESBL and AmpC is essential for enhanced infection control and effective anti-microbial therapy. There is no CLSI described guidelines for the detection of multiple β-lactamases. There is a paucity of data from Indian laboratories on the coexistence of multiple beta lactamases in individual isolates. Possible approaches to overcome this difficulty of ESBL detection in the presence of AmpC include the use of tazobactam or sulbactam, which are much less likely to induce AmpC β-lactamases or preferable use of inhibitors to ESBL detection tests [24] . All AmpC enzymes can hydrolyze cephamycins except ACC-1, which makes this drug better screening agents for AmpC production [28] .
In the present study cefoxitin resistance was seen in 86/259 (33.20%) isolates. All the 67 (100%) AmpC producing isolates (100%) showed resistance to cefoxitin disc, but only 62/67 (93%) showed ≥ 5mm zone diameter with FOX+BA discs. None of the cefoxitin sensitive isolates showed AmpC production. The isolate which does not harbor AmpC, zone sizes of disks containing FOX and FOX+BA were the same. Modified three dimensional extract method detected 61 isolates (91%) as AmpC producers. All the negatives were identified correctly ( Table 3) . FOX resistance in isolates that did not show any enhancement with the addition of BA, resistance may be due other mechanisms like porin channel alterations in these isolates. Our study correlated with that of Song et al. [20] who showed 97.7% sensitive for AmpC detection by FOX-BA method, where our study showed 91% sensitivity. Pure AmpC β-lactamases were detected only in 5.40 % of the isolates. This prevalence was lower than compared to the reports from other parts of the world [12, 29] . Two Indian studies reported 8 and 43% prevalence of AmpC β-lactamases [15, 30] . In all these AmpC producers, we were not able to distinguish between the chromosomal derepressed and plasmid mediated enzymes as this requires genotypic confirmatory tests. In our study ESBL and AmpC co producing isolates were predominantly from K. pneumonia (35.59%) followed by E. coli (15.65%). Isolates producing both ESBL and AmpC showed greater resistance to most of the antibiotics. Greater resistance to β-lactam and non β-lactam antibiotics was evident in isolates coproducing both ESBL and AmpC producers than in pure ESBL/AmpC isolates. Combination of β-lactam/ β-lactam inhibitor showed greater activity in both groups, this is likely to be due to the heavy selection pressure from overuse of these antibiotics and seem to be losing the battle [31] . Piperacillin/ tazobactum showed less resistance as compared to ticarcillin/ clavulanic acid and amoxycillin/ clavulanic acid. Among aminoglycosides, amikacin showed grater activity against all the isolates irrespective of their resistance status ( Table  4) . Sensitivity to imipenem was observed to be 100 %, which is in concordance with the studies conducted by other workers. Sensitivity to imipenem, which again advocates the usage of carbapenem antibiotics as the therapeutic alternative to β-lactam antibiotics as indicated in many studies [32, 33] .
Conclusion
A mixed type of drug resistance mechanisms seem to operate in the isolates tested. The results of the study indicate that the current CLSI recommended methods to confirm ESBL enzymes by conducting clavulanate synergy tests with ceftazidime and cefotaxime may be insufficient for ESBL detection in clinical isolates of Enterobacteriaceae since these organisms often produce multiple β-lactamses. Inhibitor based method using boronic acid disc test, practical and efficient method that uses current CLSI methodology to detect co-producing ESBL and AmpC β-lactamase is a suitable alternative to test ESBL.
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